Al­ny­lam nabs speedy re­view, set­ting up 3rd pos­si­ble ap­proval in 3 years

Af­ter near­ly two decades in the haze of pre­clin­i­cal and clin­i­cal de­vel­op­ment, things seem to be com­ing in­to fo­cus for Al­ny­lam Phar­ma­ceu­ti­cals.

Two years ago the com­pa­ny land­ed the first ap­proved drug for RNA in­ter­fer­ence (RNAi), a No­bel Prize-win­ning tech­nique dis­cov­ered in plants and pi­o­neered around the turn of the cen­tu­ry. Then last year, they land­ed an­oth­er ap­proval. Now, fresh off a mas­sive in­vest­ment from Black­stone, they’ve re­ceived an FDA pri­or­i­ty re­view des­ig­na­tion for a third ther­a­py, set­ting them up to po­ten­tial­ly nab three dif­fer­ent ap­provals in three con­sec­u­tive years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.